Next-Generation Sequencing in Breast Cancer Management: A Case Report of Genomic Tumour Evolution over Time

The clinicopathological breast cancer subtypes are used in clinical practice to better anticipate biological behaviour and guide systemic treatment strategy. In the adjuvant setting, genomic assay recurrence scores became widely available for luminal-like disease. Recently, next-generation sequencin...

Full description

Bibliographic Details
Main Authors: Marta Vaz Batista, Diogo Alpuim Costa, Paula Borralho, Sofia Braga
Format: Article
Language:English
Published: Karger Publishers 2021-08-01
Series:Case Reports in Oncology
Subjects:
Online Access:https://www.karger.com/Article/FullText/517441
id doaj-2aa9d261ac824847a3ca21ce6eea19ea
record_format Article
spelling doaj-2aa9d261ac824847a3ca21ce6eea19ea2021-09-16T08:40:56ZengKarger PublishersCase Reports in Oncology1662-65752021-08-011421212121910.1159/000517441517441Next-Generation Sequencing in Breast Cancer Management: A Case Report of Genomic Tumour Evolution over TimeMarta Vaz Batista0https://orcid.org/0000-0001-5791-2092Diogo Alpuim Costa1https://orcid.org/0000-0002-1377-3032Paula Borralho2https://orcid.org/0000-0002-8556-2090Sofia Braga3https://orcid.org/0000-0002-3163-0174Oncology Department, Hospital Professor Doutor Fernando Fonseca EPE, Amadora, PortugalHaematology and Oncology Department, CUF Oncologia, Lisboa, PortugalPathology Department, CUF Oncologia, Lisbon, PortugalOncology Department, Hospital Professor Doutor Fernando Fonseca EPE, Amadora, PortugalThe clinicopathological breast cancer subtypes are used in clinical practice to better anticipate biological behaviour and guide systemic treatment strategy. In the adjuvant setting, genomic assay recurrence scores became widely available for luminal-like disease. Recently, next-generation sequencing (NGS) platforms have been used, essentially, in more advanced disease setting, in situations refractory to conventional treatment, or even in rare cancers for which there are no established treatment guidelines. Moreover, subpopulations of cancer cells with unique genomes within the same patient may exist across different regions of a tumour or evolve over time, which is called intratumoural heterogeneity. We herein report a case of a 38-year-old woman with breast cancer whose primary and metastatic disease exhibited discordant expression of hormone receptors, with the former being positive and the latter negative. Furthermore, the NGS analysis revealed slight and dynamic changes of mutational profiles between different metastatic lesions, potentially impacting breast cancer management and prognosis. These alterations may reflect tissular and temporal changes in tumour subclones and may also be due to the selective pressure caused by antineoplastic treatment. The use of genomic analyses in order to improve cancer treatment has been studied prospectively with encouraging results. The widespread use of NGS tests in clinical practice also creates new challenges. The most relevant may be to know which genomic alterations detected should be valued and how they should be targeted.https://www.karger.com/Article/FullText/517441case reportnext-generation sequencingmetastatic breast cancerbreast cancer in young
collection DOAJ
language English
format Article
sources DOAJ
author Marta Vaz Batista
Diogo Alpuim Costa
Paula Borralho
Sofia Braga
spellingShingle Marta Vaz Batista
Diogo Alpuim Costa
Paula Borralho
Sofia Braga
Next-Generation Sequencing in Breast Cancer Management: A Case Report of Genomic Tumour Evolution over Time
Case Reports in Oncology
case report
next-generation sequencing
metastatic breast cancer
breast cancer in young
author_facet Marta Vaz Batista
Diogo Alpuim Costa
Paula Borralho
Sofia Braga
author_sort Marta Vaz Batista
title Next-Generation Sequencing in Breast Cancer Management: A Case Report of Genomic Tumour Evolution over Time
title_short Next-Generation Sequencing in Breast Cancer Management: A Case Report of Genomic Tumour Evolution over Time
title_full Next-Generation Sequencing in Breast Cancer Management: A Case Report of Genomic Tumour Evolution over Time
title_fullStr Next-Generation Sequencing in Breast Cancer Management: A Case Report of Genomic Tumour Evolution over Time
title_full_unstemmed Next-Generation Sequencing in Breast Cancer Management: A Case Report of Genomic Tumour Evolution over Time
title_sort next-generation sequencing in breast cancer management: a case report of genomic tumour evolution over time
publisher Karger Publishers
series Case Reports in Oncology
issn 1662-6575
publishDate 2021-08-01
description The clinicopathological breast cancer subtypes are used in clinical practice to better anticipate biological behaviour and guide systemic treatment strategy. In the adjuvant setting, genomic assay recurrence scores became widely available for luminal-like disease. Recently, next-generation sequencing (NGS) platforms have been used, essentially, in more advanced disease setting, in situations refractory to conventional treatment, or even in rare cancers for which there are no established treatment guidelines. Moreover, subpopulations of cancer cells with unique genomes within the same patient may exist across different regions of a tumour or evolve over time, which is called intratumoural heterogeneity. We herein report a case of a 38-year-old woman with breast cancer whose primary and metastatic disease exhibited discordant expression of hormone receptors, with the former being positive and the latter negative. Furthermore, the NGS analysis revealed slight and dynamic changes of mutational profiles between different metastatic lesions, potentially impacting breast cancer management and prognosis. These alterations may reflect tissular and temporal changes in tumour subclones and may also be due to the selective pressure caused by antineoplastic treatment. The use of genomic analyses in order to improve cancer treatment has been studied prospectively with encouraging results. The widespread use of NGS tests in clinical practice also creates new challenges. The most relevant may be to know which genomic alterations detected should be valued and how they should be targeted.
topic case report
next-generation sequencing
metastatic breast cancer
breast cancer in young
url https://www.karger.com/Article/FullText/517441
work_keys_str_mv AT martavazbatista nextgenerationsequencinginbreastcancermanagementacasereportofgenomictumourevolutionovertime
AT diogoalpuimcosta nextgenerationsequencinginbreastcancermanagementacasereportofgenomictumourevolutionovertime
AT paulaborralho nextgenerationsequencinginbreastcancermanagementacasereportofgenomictumourevolutionovertime
AT sofiabraga nextgenerationsequencinginbreastcancermanagementacasereportofgenomictumourevolutionovertime
_version_ 1717378293934587904